HumaScan's marketing efforts for its BreastAlert Differential Temperature Sensor (DTS) system have drawn the attention of the Food and Drug Administration. In an April 24 warning letter to the Cranford, NJ-based company, the agency's Center for Devices
HumaScan's marketing efforts for its BreastAlert Differential Temperature Sensor (DTS) system have drawn the attention of the Food and Drug Administration. In an April 24 warning letter to the Cranford, NJ-based company, the agency's Center for Devices and Radiological Health took issue with advertisements, physician labeling, comments by celebrity spokespersons, and press releases associated with BreastAlert, a noninvasive adjunctive screening device for breast cancer (SCAN 7/9/97). HumaScan holds U.S. and Canadian marketing rights from Scantek Medical, which developed the product.
In particular, the CDRH's warning letter stated that the company has misrepresented the intended use of the device, making both implicit and explicit claims that the device can detect breast disease, including breast cancer. The device was cleared as an adjunct to routine physical examination, including palpation, mammography, and other established procedures for the detection of breast disease. HumaScan officials were not immediately available for comment.
In other company news, HumaScan and BreastAlert's developer, Scantek Medical of Denville, NJ, have restructured their licensing agreement. The move, which was made to provide HumaScan with additional time and financing to pursue its marketing and distribution plans, waives certain HumaScan royalty payments in exchange for HumaScan stock warrants.
HumaScan has also restructured its contract with Zigmed, which provides production equipment for BreastAlert. The purchase price for the equipment has been reduced by approximately $200,000 in exchange for the issuance of warrants to purchase 30,000 shares of HumaScan's common stock at $4.725 per share.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.